 |
11th Winter Conference on Medicinal & Bioorganic Chemistry
January 20, 2013–January 24, 2013
Steamboat Springs, Colorado
Quality by Design
January 23, 2013–January 24, 2013
London, United Kingdom Social Media in the Pharmaceutical Industry
January 23, 2013–January 24, 2013
London, United Kingdom Pre-Filled Syringes
January 28, 2013–January 29, 2013
London, United Kingdom CBI's 4th Annual Effective Preparation for FDA Advisory Committee Meetings
February 5, 2013–February 6, 2013
Washington, DC
|
|
|
 |
 
 |
 Probe enables monitoring of in-process vacuum
Hiden Analytical’s in-process vacuum monitor, the HALO 201 MBE, was initially designed for application to the molecular beam epitaxy process and is suitable for use in difficult process conditions. Many vacuum-related processes operate at high- or ultra-high vacuum levels that represent a difficult environment for quadrupole mass spectrometers, but the sensitive ionisation region of the HALO 201 MBE probe is completely shrouded to inhibit random surface deposition. With a mass range of 1–200 amu, the probe can be used for measuring all common gasses and contaminants, and features operating modes for vacuum species identification, leak detection, and process trend analysis.
|
|
|
 |
| Malvern Instruments has opened a new applications laboratory in São Paulo, Brazil, to support business growth in South America. The facility will be equipped with instruments spanning Malvern’s range of particle characterization, protein measurement, and rheology systems.
Roche plans to invest more than CHF 240 million (USD 263 million) in diagnostics production at its Penzberg biotechnology center near Munich, Germany. The plans call for construction of a new production facility, to be known as Diagnostics Operations Complex II. The facility is scheduled to be operational in December 2014 and will create 50 new jobs. Read More
Teva Pharmaceutical Industries and Handok Pharmaceuticals have agreed to establish a business venture in South Korea, allowing Teva to gain entrance into the Korean pharmaceutical market. Under the agreement, Teva will be responsible for manufacturing and supplying medicines. Handok’s primary responsibility will be in sales and marketing, distribution, and regulatory affairs. Teva will have a controlling stake in the new business venture, with a profit split of 51/49% to Teva and Handok, respectively. Read More
A roundup of additional company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers. Read More
Do you have news to report on facility expansions, contracts, service agreements, mergers, acquisitions, or personnel appointments? Send press releases to [email protected] |
|
|
|
 |
| Job Security |
by: Amy Ritter
Annual employment survey results show greater confidence in the pharmaceutical industry.
 |
Coming soon: Pharm Tech’s January issue explores x-ray powder diffraction pattern indexing for pharmaceutical applications. |
|
|
Know Before You Go—2012 Conference Previews
Visit our Show & Exhibition Gateway 2012 to see which companies are exhibiting at upcoming industry conferences.
Find company backgrounds, new product releases, booth materials, and more.
PharmTech's online
Gateway is your guide to the season's leading shows.
|
|
|
|
|
|
